Top
This page is only for information of and use by registered medical practitioners. Other persons are advised not to act on the basis of information contained in this page. They are requested to consult registered medical practitioner.
Azilsartan-medoxomil-Myotan-CN

Myotan CN 40/10 (Azilsartan Medoxomil and Cilnidipine Tablets) is a fixed dose combination drug containing Azilsartan Medoxomil Tablet and Cilnidipine Tablets and is used in the treatment of hypertension. Myotan CN is is marketed by J.B. Chemicals & Pharmaceuticals Ltd.


Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.


Azilsartan medoxomil is rapidly hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption.


Cilnidipine is a third generation dihydropyridine calcium antagonist with a slow onset and long duration of action. Calcium antagonists inhibit influx of extracellular calcium ions into the cells, resulting in decreased vascular smooth muscle tone and vasodilation, leading to a reduction in blood pressure.


In human studies, cilnidipine had weak inotropic effects and suppressed cardiac sympathetic overactivity. Therefore it may decrease the risk and mortality from long term cardiovascular complications. Once-daily cilnidipine was associated with less reflex tachycardia and had fewer effect on the autonomic nervous system in hypertensive patients.

Overview
Name of Product: MYOTAN® CN 40/10
Marketed by : J.B. Chemicals & Pharmaceuticals Ltd.
Medicine composition: Each film coated bilayered tablet contains:
Azilsartan Kamedoxomil
Equivalent to Azilsaratan Medoxomil…………40 mg
Cilnidipine IP………………………………….10 mg
Excipients……………………………………….q.s.
Colours: Tartrazine Lake and Titanium Dioxide IP
Prescription vs.OTC: Prescription by Doctor required
Dosage Form: Film coated tablets

Myotan CN is indicated for the treatment of hypertension, to lower blood pressure.

Recommended Dose

Starting dose is 40/5 mg once daily

  • The recommended adult oral dosage of Cilnidipine is 5-10 mg once daily.
  • Dose may be increased to 40/10 mg after 2 to 4 weeks as needed to achieve blood pressure goals.
  • Maximal dose is 40/10 mg.
  • May be administered with other antihypertensive agents.

Azilsartan: Do not coadminister aliskiren-containing products with Azilsartan in patients with diabetes.


Cilnidipine: Cilnidipine is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to Cilnidipine or any other component of this product.

Download Leaflet for details on Contraindications.

Azilsartan should not be used in following cases or should be used carefully in following cases

  • Fetal Toxicity (Pregnancy)
  • Hypotension in Volume- or Salt-Depleted Patients
  • Impaired Renal Function

Cilnidipine is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to Cilnidipine or any other component of this product.

Download Leaflet to see the detailed warnings and precautions.

Azilsartan may have drug interactions with the following drugs

  • Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
  • Dual Blockade of the Renin-Angiotensin System (RAS)
  • Lithium

Cilnidipine can interact with aldesleukin, quinidine, phenytoin, rifampicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drugs.

Download the Product Leaflet, to see the detailed drug interactions.

Studies show that treatment with Azilsartan is well-tolerated with an overall incidence of adverse reactions similar to placebo. The most common adverse event leading to discontinuation was hypotension/orthostatic hypotension. Some other side effects may include Gastrointestinal Disorders: nausea, Diarrhea, General Disorders and Administration Site Conditions: asthenia, fatigue , Musculoskeletal and Connective Tissue Disorders: muscle spasm .

Nervous System Disorders: dizziness, dizziness postural, Respiratory, Thoracic, and Mediastinal Disorders: cough.

Check with your doctor immediately if any of the following side effects occur:

  • Feeling like you might pass out
  • Uinating less than usual or not at all
  • drowsiness, confusion, mood changes, increased thirst, loss of appetite
  • Swelling, weight gain, feeling short of breath; or
  • electrolyte imbalance (dry mouth, extreme thirst, drowsiness, restless feeling, confusion, increased or decreased urination, constipation, muscle pain or weakness, fast heart rate, or seizure (convulsions)).

Other common side effects may include
  • mild skin rash
  • diarrhea, nausea, upset stomach;
  • cough
  • mild dizziness; or
  • Weakness, tired feeling.

Download the Product Leaflet, to see the the detailed information on the Undesirable Side effects/ Overdose.

Download the Product Leaflet, to see the details on Pharmacodynamic and Pharmacokinetic Properties of Myotan CN 40/10

Contact us for further information

Myotan CN 40/10 (Azilsartan Medoxomil and Cilnidipine Tablets) is a fixed dose combination drug containing Azilsartan Medoxomil Tablet and Cilnidipine Tablets and is used in the treatment of hypertension. Myotan CN is is marketed by J.B. Chemicals & Pharmaceuticals Ltd.


Azilsartan inhibits the pressor effects of an angiotensin II infusion in a dose-related manner. Azilsartan blocks the vasoconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is, therefore, independent of the pathway for angiotensin II synthesis.


Azilsartan medoxomil is rapidly hydrolyzed to azilsartan, the active metabolite, in the gastrointestinal tract during absorption.


Cilnidipine is a third generation dihydropyridine calcium antagonist with a slow onset and long duration of action. Calcium antagonists inhibit influx of extracellular calcium ions into the cells, resulting in decreased vascular smooth muscle tone and vasodilation, leading to a reduction in blood pressure.


In human studies, cilnidipine had weak inotropic effects and suppressed cardiac sympathetic overactivity. Therefore it may decrease the risk and mortality from long term cardiovascular complications. Once-daily cilnidipine was associated with less reflex tachycardia and had fewer effect on the autonomic nervous system in hypertensive patients.

JOURNAL UPDATE


• Effects of Olmesartan and Azilsartan on Albuminuria and the Intrarenal Renin-Angiotensin System.

• Azilsartan: Current Evidence and Perspectives in Management of Hypertension.

X
X